Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.
Ravi Vij, MD, MBA, professor, Department of Medicine, Oncology Division, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, medical director, Siteman Cancer Center, Barnes West County Hospital, Barnes St. Peter’s Hospital, South County Satellite, discusses the potential of cereblon E3 ligase modulators (CELMoDs) in relapsed/refractory multiple myeloma.
Historically, immunomodulatory agents (IMiDs), such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), have served as a therapeutic backbone across the paradigm of multiple myeloma, says Vij. Looking forward, it is possible that CELMoDs will become the next generation of IMiDs, Vij adds.
CELMoDs are designer molecules that attach to the cereblon molecule, which is the main target of IMiDs, Vij explains. Early efficacy data have demonstrated good response rates with CELMoDs without significant hematologic toxicity in heavily pretreated patients, Vij says. Currently, the CELMoDs iberdomide (formerly CC-220) and CC-92480 are in clinical development, concludes Vij.